Neurogene Inc (NGNE) Stock Forecast & Price Target

Neurogene is supported by compelling Phase 1/2 Embolden data for NGN-401, where 8/10 patients met the pivotal composite endpoint versus a 33% success threshold and 10/10 improved on CGI-I while gaining at least one developmental milestone. The durability and breadth of response are notable, with average milestones rising from 1.9 at six months to 4.7 at ≥12 months, 47 total milestones gained, no plateau through up to 30 months, and a generally well tolerated safety profile across 35 treated patients. Financially, the recent ~$135M financing lifted pro forma cash to about $360.2M and extended runway into 1Q29, giving the company room to complete PPQ by YE26 and reach the 2H27 data readout without a financing overhang.

Neurogene is viewed negatively because its lead program faces multiple fundamental risks that could undermine both approval and adoption, including safety concerns at the current 1E15 vg dose, the possibility that registrational response rates fall well short of the 80% observed to date versus the 35% required, and regulatory uncertainty after prior FDA alignment on the EMBOLDEN dataset was reversed. Although NGN-401 showed 35 total skills gained across eight pediatric participants with no skills lost and no HLH cases across 35 treated patients as of June 7th, the 12+ months of follow-up for all 10 Phase 1/2 participants will need to prove durability, functional translation, and consistency in adolescents/adults to support the 12-month registrational approach. The commercial case is also fragile because ICV administration is a bigger hurdle than assumed and Rett syndrome is non-degenerative, so caregivers may delay a one-time therapy; with only $1.7B EV, a 55% probability of approval, and long-term dilution risk, the stock appears vulnerable.